MedElevator Войти в исследования
← Поиск публикаций

DOI 10.59556/japi.71.0426

Медицинская библиотека · The Journal of the Association of Physicians of India · 2023

Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.

Chopra H K, Nair Tiny, Wander G S, Ponde C K, Ray Saumitra, Khullar Dinesh, Nanda Navin C, Kasliwal Ravi R, Rana D S, Kirpalani Ashok, Sawhney J P S, Chandra Praveen, Mehta Yatin, Kumar Viveka, Tewari S, Pancholia A K, Kher Vijay, Bansal Sandeep, Mittal Sanjay, Kerkar Praful, Sahoo P K, Hotchandani Ramesh, Prakash Sunil, Chauhan Nagendra, Rastogi Vishal, Jabir A, Shanmugasundaram S, Tiwaskar Mangesh, Sinha Ajay, Gupta Vittul, Mishra S S, Routray S N, Omar A K, Swami Onkar C, Jaswal Aparna, Alam Shamsad, Passey Rajeev, Rajput Rajeeve, Paul Justin, Kapoor Aditya, Prabhakar D, Chandra Subhash, Malhotra Poonam, Singh Vivudh Pratap, Bansal Manish, Shah Priyank, Jain Sanjay, Bhargava Mohan, Vijayalakshmi I B, Varghaese Kiron, Jain Dharmender, Goel Anupam, Gaur Namrata, Tandon Rohit, Moorthy Asha, George Sheeba, Katyal V K, Mantri R R, Mehrotra Rahul, Bhalla Dilip, Mittal Vinod, Rao Sarita, Jagia Manish, Singh Harmeet, Awasthi Surabhi, Sattur Ameet, Mishra Rekha, Pandey Anand, Chawla Rajeev, Jaggi Shalini, Sehgal Blessy, Sehgal Alok, Goel Naresh, Gupta Ripen, Kubba Samir, Chhabra Abhinav, Bagga Saurabh, Shastry N R

СтатьяConsensus StatementПеревод пока не подготовлен

Аннотация

In India, heart failure (HF) is an important health concern affecting younger age groups than the western population. A limited number of Indian patients receive guideline-directed medical therapy (GDMT). Selective β-1 blockers (BB) are one of the GDMTs in HF and play an important role by decreasing the sympathetic overdrive. The BB reduces heart rate (HR) reverse the adverse cardiac (both ventricular and atrial), vascular, and renovascular remodeling seen in HF. Bisoprolol, a β-1 blocker, has several advantages and can be used across a wide spectrum of HF presentations and in patients with HF and comorbid conditions such as coronary artery disease (CAD), atrial fibrillation (AF), post-myocardial infarction (MI), uncontrolled diabetes, uncontrolled hypertension, and renal impairment. Despite its advantages, bisoprolol is not optimally utilized for managing HF in India. This consensus builds on updated evidence on the efficacy and safety of bisoprolol in HF and recommends its place in therapy with a focus on Indian patients with HF.

Для цитирования: Chopra H K, Nair Tiny, Wander G S, Ponde C K, Ray Saumitra, Khullar Dinesh, Nanda Navin C, Kasliwal Ravi R, Rana D S, Kirpalani Ashok, Sawhney J P S, Chandra Praveen, Mehta Yatin, Kumar Viveka, Tewari S, Pancholia A K, Kher Vijay, Bansal Sandeep, Mittal Sanjay, Kerkar Praful, Sahoo P K, Hotchandani Ramesh, Prakash Sunil, Chauhan Nagendra, Rastogi Vishal, Jabir A, Shanmugasundaram S, Tiwaskar Mangesh, Sinha Ajay, Gupta Vittul, Mishra S S, Routray S N, Omar A K, Swami Onkar C, Jaswal Aparna, Alam Shamsad, Passey Rajeev, Rajput Rajeeve, Paul Justin, Kapoor Aditya, Prabhakar D, Chandra Subhash, Malhotra Poonam, Singh Vivudh Pratap, Bansal Manish, Shah Priyank, Jain Sanjay, Bhargava Mohan, Vijayalakshmi I B, Varghaese Kiron, Jain Dharmender, Goel Anupam, Gaur Namrata, Tandon Rohit, Moorthy Asha, George Sheeba, Katyal V K, Mantri R R, Mehrotra Rahul, Bhalla Dilip, Mittal Vinod, Rao Sarita, Jagia Manish, Singh Harmeet, Awasthi Surabhi, Sattur Ameet, Mishra Rekha, Pandey Anand, Chawla Rajeev, Jaggi Shalini, Sehgal Blessy, Sehgal Alok, Goel Naresh, Gupta Ripen, Kubba Samir, Chhabra Abhinav, Bagga Saurabh, Shastry N R. Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.. The Journal of the Association of Physicians of India. 2023. DOI: 10.59556/japi.71.0426.

Предметные рубрики MeSH

HumansBisoprololHeart FailureIndiaAdrenergic beta-1 Receptor Antagonists
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.